Dr. Pollard Brings the Highest Level of Clinical Immunology Expertise
MCLEAN, Va. and BUDAPEST, Hungary, Feb. 1 /PRNewswire/ -- Genetic Immunity(R), a US/Hungarian clinical-stage biopharmaceutical company focused on the development and commercialization of its patented immunotherapeutic platform technology, announced that it has appointed Richard B. Pollard, M.D. as Chief Medical Officer.
Dr. Pollard has been a leader in HIV/AIDS research for more than twenty years; he cared for his first patient with AIDS in 1982, and continues to provide primary care for hundreds of patients with HIV and related conditions. Dr. Pollard has been involved in the development of new treatments for the HIV, herpes, and hepatitis viruses. His laboratory, one of the five immunology specialty laboratories supported by the AIDS Clinical Trials Group (ACTG), performs multiple assays to monitor immunologic changes to HIV and opportunistic viral pathogens.
In addition, Dr. Pollard is Professor of Internal Medicine and Microbiology and Chief of the Division of Infectious Diseases at the University of California, Davis Medical School in Sacramento, CA. He currently serves as the Principal Investigator of the Immunology Specialty Laboratory, Chair of the ACTG Laboratory Evaluation Subcommittee, and Principal Investigator of the California Research Center for the Biology of HIV in Minorities.
Dr. Pollard said, "I'm excited to join Genetic Immunity's scientifically strong team; I believe that this team has the depth to develop scalable in vivo immunotherapies from the research stage though clinical development in a number of indications. As someone who has spent a quarter century active in AIDS care, I'm excited to work on the DermaVir Patch product as it is one of the most innovative approaches to HIV treatment. As a researcher, I'm impressed that an exceptional clinical observation inspired a new immune therapy technology."
Julianna Lisziewicz, Ph.D., Co-
|SOURCE Genetic Immunity|
Copyright©2008 PR Newswire.
All rights reserved